Our Website Uses Cookies 


We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website.


For more information, please contact us or consult our Privacy Notice.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Covington Advises King Pharmaceuticals in Sale of PrefestĀ® to Barr Subsidiary

November 30, 2004

WASHINGTON, D.C., November 30, 2004 -  Covington & Burling recently assisted King Pharmaceuticals, Inc. (NYSE: KG) in its sale to Duramed Pharmaceuticals, Inc., a subsidiary of Barr Pharmaceuticals, Inc. (NYSE: BRL), of the exclusive rights in the United States for Prefest® (estradiol/norgestimate) Tablets.  The sale price was approximately $15 million.

King Pharmaceuticals focuses on the development of novel branded prescription pharmaceutical products in attractive markets and the strategic acquisition of branded products that can benefit from focused promotion and marketing.

The Covington team was led by John Hurvitz, Ed Dixon, and Sean Reid.  Marie Lavalleye and Andrea Reister assisted on intellectual property matters.

Share this article: